[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349920-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-349920-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","proton-beam-therapy-in-gynecological-cancers-a-systematic-review-of-indications-complications-and-limitations","Proton Beam Therapy in Gynecological Cancers - A Systematic Review of Indications, Complications, and Limitations","","Systematic review evaluating proton beam therapy (PBT) for gynecological cancers requiring radiation therapy in primary, adjuvant, or salvage settings. The review addresses the toxicity limitations of photon-based radiotherapy, especially for pelvic recurrences after prior irradiation, and summarizes evidence gaps in gynecologic oncology. Following PRISMA guidance and PROSPERO registration, studies from 2000–2025 were screened; 9 studies (232 patients) met criteria. Severe GI and GU toxicity was uncommon overall (15.2%), lower in adjuvant/de novo series, and higher in re-irradiation cohorts, with limited comparative data versus IMRT.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/proton-beam-therapy-in-gynecological-cancers-a-systematic-review-of-indications-complications-and-limitations/349920/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/proton-beam-therapy-in-gynecological-cancers-a-systematic-review-of-indications-complications-and-limitations/349920.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What patient settings and cancer types does the review focus on?","Question",{"text":63,"@type":64},"It focuses on gynecological cancers needing radiation therapy in primary, adjuvant, or salvage contexts, including endometrial and cervical cancers, and addresses especially pelvic recurrences after prior irradiation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were adverse events categorized and graded in the study?",{"text":68,"@type":64},"Adverse events were categorized as GI, GU, or other, and only grade ≥3 CT-CAE complications were considered for the outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings on severe toxicity after proton beam therapy?",{"text":72,"@type":64},"Overall severe toxicity occurred in 15.2% of patients, with GI complications ranging from 0–14% and GU from 0–33%. Rates were lowest in adjuvant or de novo series (0–10%), while re-irradiation cohorts showed higher rates.",{"name":74,"@type":61,"acceptedAnswer":75},"Is proton beam therapy considered a standard treatment for gynecological oncology?",{"text":76,"@type":64},"The review concludes that current evidence is limited to small, heterogeneous studies, so PBT in gynecologic oncology should be regarded as investigational until ongoing phase II trials provide prospective feasibility, toxicity, and long-term outcomes.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},349920,1790929266,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Systematic Review  \nProton Beam Therapy in Gynecological Cancers: A Systematic Review of Indications, Complications, and Limitations  \nVito Andrea Capozzi 1,†, Giulia Martignon 1,†, Elisa Scarpelli 2, *, Alessandra De Finis 1, Stefano Restaino 3, Giuseppe Vizzielli 3,4 and Roberto Berretta 1  \nAcademic Editor: Masafumi Koshiyama  \nReceived: 21 December 2025  \nRevised: 25 January 2026  \nAccepted: 4 February 2026  \nPublished: 6 February 2026  \nCopyright: © 2026 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy  \n2 Department of Medicine and Surgery, Doctoral School in Health Sciences and Technology, University of Bologna, 40126 Bologna, Italy  \n3 Clinic of Obstetrics and Gynecology,“Santa Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy  \n4 Medical Area Department (DAME), University of Udine, 33100 Udine, Italy  \n* Correspondence: [elisascarpelli13@gmail.com](elisascarpelli13@gmail.com)  \n† These authors contributed equally to this work.  \nAbstract  \nBackground and Objectives: Gynecological cancers frequently require radiation therapy (RT) in primary, adjuvant, or salvage settings. However, photon-based RT is associated with non-negligible toxicity, and treatment of pelvic recurrences after prior irradiation remains challenging. Proton beam therapy (PBT), due to its favorable dose distribution and reduced exposure of organs at risk (OARs), has emerged as a potential alternative, particularly in reirradiation scenarios. Despite its expanding use in other malignancies, evidence supporting PBT in gynecologic cancers remains limited. This systematic review aims to investigate the use of PBT in gynecological cancers and its associated complications. Materials and Methods: This systematic review was conducted according to PRISMA guidelines and registered in PROSPERO. A comprehensive search (2000–2025) identified studies investigating PBTin gynecologic cancers. Eligible designs included randomized trials and prospective and retrospective series. Reported adverse events were categorized as GI, GU, or other, and only grade ≥3 CT-CAE complications were considered. Results: Of 580 records screened, 9 studies comprising 232 patients met inclusion criteria. Most patients were treated for endometrial (n = 147) or cervical (n = 75) cancer; 90 received chemotherapy. Overall, severe toxicity occurred in 15.2% of patients. GI complications ranged from 0–14% and GU from 0–33% . Complication rates were lowest in adjuvant or de novo treatment series (0–10%), whereas re-irradiation cohorts showed higher rates (up to 33% GU) . Comparative studies suggested a possible advantage of PBT over IMRT, particularly for GI toxicity, though data remain limited. Conclusions: Severe GI and GU toxicity after PBT in gynecologic cancers appears infrequent, particularly in primary and adjuvant settings, though reirradiation remains challenging. Current evidence is restricted to small and heterogeneous studies. Ongoing phase II trials will provide prospective data to clarify feasibility, toxicity, and long-term outcomes. Until then, PBT in gynecologic oncology should be regarded as investigational.  \nKeywords: proton beam therapy; gynecological cancer; reirradiation  \n1. Introduction  \nGynecological cancers affect nearly 1.4 million women worldwide each year, with cervical and endometrial cancers ranking as the second and sixth most common malignancies in women, respectively [1] . Radiation therapy (RT), traditionally delivered with photon-based external beam radiotherapy (EBRT), plays a prominent role in the treatment of gynecological malignancies, either as an exclusive or in combination with chemotherapy","cbCaicDg4PmwrVs5","https://ap.wps.com/l/cbCaicDg4PmwrVs5","pdf",587540,15,"English","# Abstract\n## Background and Objectives\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What patient settings and cancer types does the review focus on?\",\"answer\":\"It focuses on gynecological cancers needing radiation therapy in primary, adjuvant, or salvage contexts, including endometrial and cervical cancers, and addresses especially pelvic recurrences after prior irradiation.\"},{\"question\":\"How were adverse events categorized and graded in the study?\",\"answer\":\"Adverse events were categorized as GI, GU, or other, and only grade ≥3 CT-CAE complications were considered for the outcomes.\"},{\"question\":\"What were the main findings on severe toxicity after proton beam therapy?\",\"answer\":\"Overall severe toxicity occurred in 15.2% of patients, with GI complications ranging from 0–14% and GU from 0–33%. Rates were lowest in adjuvant or de novo series (0–10%), while re-irradiation cohorts showed higher rates.\"},{\"question\":\"Is proton beam therapy considered a standard treatment for gynecological oncology?\",\"answer\":\"The review concludes that current evidence is limited to small, heterogeneous studies, so PBT in gynecologic oncology should be regarded as investigational until ongoing phase II trials provide prospective feasibility, toxicity, and long-term outcomes.\"}]","Proton Beam Therapy in Gynecological Cancers - A Systematic Review of Indications, Complications, and Limitations | PDF",1790086249,38,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab18d45b0091880acb80f4635b3fbb9a.webp",983,1390,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49f73e41e994b3c36151564788b14183.webp",982,1388,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42bbeb43784e95196c9c199db326dfe4.webp",981,1387,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2134d7ae2f4f70dfcd55707221ad1a45.webp",980,1385]